PLTs were obtained after blood fractionation, yielding a PLT-rich plasma solution. To prevent mechanical activation of PLTs, further centrifugation was avoided.(37) Initial verification of PLT viability was performed using flow-cytometry. To avoid overflow, PLT-rich plasma was diluted by transferring 5 μL of solution in 295 μL of PBS in a 96-well for flow-cytometry analysis. Forward and side scatter were used to correlate signal with cell size. The final solution was prepared by mixing PLT-rich plasma in PBS at a ratio 1:3, namely 250 μL in 750 μL of PBS. Using gentle mixing to avoid activation, a homogeneous solution of PLT-rich plasma and PBS was considered for the treatment (control, distilled water, and IONFs concentrations). The treatment was added in a ratio of 1:10 of the PBS component into an Eppendorf cuvette.